相关实验视频

Updated: Jul 6, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

在高风险肝细胞癌患者的术后辅助免疫疗法

Wei-Qiao Zhang¹, Qiao Zhang², Li Tan³

¹Guangdong Medical College, Zhanjiang, China.

Frontiers in oncology

|January 5, 2024

概括

手术后的抗PD-1抗体治疗显著改善了肝切除术后高风险肝细胞癌 (HCC) 患者的存活率和无复发存活率. 这种辅助治疗为改善患者长期预后提供了一个有希望的策略.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
肝胆道手术肝胆道手术

背景情况:

缺乏针对肝细胞癌 (HCC) 的标准化术后辅助疗法.
鉴定肝切除术后高风险HCC患者的有效辅助治疗方法至关重要.

研究的目的:

评估术后PD-1辅助治疗对短期和长期结果的影响.
评估抗PD-1抗体在提高高风险HCC患者的生存率和减少复发中的有效性.

主要方法:

对从2018年6月到2023年3月接受肝切除术的HCC患者的回顾性分析.
对抗PD-1和非抗PD-1组之间的1:1比较的倾向性得分匹配 (PSM).
卡普兰-梅尔生存分析和考克斯回归用于预后因素识别.

主要成果:

与没有抗PD-1治疗相比,术后抗PD-1治疗与1至4年总生存率 (OS) 和无复发生存率 (RFS) 的显著改善有关.
考克斯回归确定了术后PD-1使用作为OS和RFS的保护性预后因素.
亚组分析证实,抗PD-1抗体在高风险HCC患者中具有实质性的益处.

结论:

术后辅助抗PD-1抗体疗法有效改善肝切除术后高复发风险的HCC患者的生存预后.
这种免疫疗法方法代表了一种有价值的策略,用于提高这种患者群体的长期结果.

关键词:

在HCC中,HCC是HCC.抗PD-1 抗体的抗体.生物标志生物标志是指生物标志.高风险的复发因素术后辅助疗法术后辅助疗法

更多相关视频

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.